Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women

  • Andreas Lammerich, Peter Bias, Beate Gertz
  • International Journal of Women s Health, July 2015, Dove Medical Press
  • DOI: 10.2147/ijwh.s83418

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication

The following have contributed to this page: Dr Andreas Lammerich and Beate Dr. Gertz